Neustadt, Germany

Frank Zimmermann


Average Co-Inventor Count = 4.9

ph-index = 2

Forward Citations = 26(Granted Patents)


Company Filing History:


Years Active: 1979-1984

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Frank Zimmermann: Innovator in Cardiovascular Treatment

Introduction

Frank Zimmermann is a notable inventor based in Neustadt, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that address cardiovascular disorders. With a total of 2 patents, his work has the potential to impact many lives.

Latest Patents

Zimmermann's latest patents include innovative compounds such as .OMEGA.-Cyano-1 and .OMEGA.-diphenyl-azaalkane derivatives. These compounds are described by the formula I, where R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, m, and n have specific meanings outlined in the patent description. These derivatives, along with their salts with physiologically tolerated acids, are particularly useful in treating cardiovascular disorders. Additionally, he has developed non-glycosidic theophylline-sugar derivatives, which are hypolipemic compounds that can be used to treat hyperlipemia.

Career Highlights

Frank Zimmermann is associated with BASF Aktiengesellschaft, a leading chemical company known for its innovative solutions. His work at BASF has allowed him to focus on research and development in the pharmaceutical sector, contributing to advancements in medical treatments.

Collaborations

Zimmermann has collaborated with notable coworkers such as Ludwig Friedrich and Oskar Ehrmann. Their combined expertise has fostered a productive environment for innovation and development in their respective fields.

Conclusion

Frank Zimmermann's contributions to the field of cardiovascular treatment through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in medical science and patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…